Rapid eye movement sleep behavior disorder

Journal Frontiers in Psychiatry Publishes Analysis of Open Label Safety Study Showing Improvements in Sleep Habits for Children With ADHD After Treatment With AZSTARYS® (serdexmethylphenidate and dexmethylphenidate)

Retrieved on: 
Monday, June 26, 2023
Central nervous system, Frontiers, Gastrointestinal tract, Speech, Overalls, Sleep, Children's Sleep Habits Questionnaire, ADHD, Medicine, CNS, Movement, Parasomnia, Schedule, Attention deficit hyperactivity disorder, Insomnia, Hydrogen chloride, MD, Patient, Central nervous system disease, Sleep disorder, Rapid eye movement sleep behavior disorder, Molar, Washington University School of Medicine, Somnolence, SDX, Ageing, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Caregiver, Safety, Dietary supplement, Pharmaceutical industry, Corium, Psychiatry

BOSTON, June 26, 2023 /PRNewswire/ -- Corium, LLC, a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today that the peer-reviewed journal Frontiers in Psychiatry published an analysis of a yearlong open-label safety study of Corium's attention-deficit hyperactivity disorder (ADHD) medicine AZSTARYS (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]). AZSTARYS was approved by the U.S. Food and Drug Administration in 2021 for the treatment of ADHD symptoms in people aged 6 years through adulthood. The analysis showed that study participants, children aged 6 to 12 years with ADHD and treated with AZSTARYS for up to twelve months, had statistically significant and lasting improvements in their sleep as assessed by the Children's Sleep Habits Questionnaire (CSHQ), a caregiver-reported screening survey designed to assess behavioral and medically based sleep problems in school children.

Key Points: 
  • AZSTARYS was approved by the U.S. Food and Drug Administration in 2021 for the treatment of ADHD symptoms in people aged 6 years through adulthood.
  • Almost three in four children with ADHD have some sleep impairment, according to Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD), a national nonprofit organization serving people affected by ADHD.
  • After one month of AZSTARYS treatment, the children's average CSHQ total sleep disturbance score significantly decreased, indicating improved sleep.
  • Moreover, after 12 months of treatment their average CSHQ total score remained in the 48.9 to 50.1 range, indicating the children sustained overall sleep improvements while receiving AZSTARYS.

A little-understood sleep disorder affects millions and has clear links to dementia – 4 questions answered

Retrieved on: 
Saturday, May 27, 2023
Blood pressure, Smell, Pure autonomic failure, Association, Conversation, Melatonin, Tremor, RBD, Rapid eye movement sleep behavior disorder, Respiratory rate, Sleep, Deficit spending, Narcolepsy, Constipation, Quality of life, Multiple system atrophy, Brain, Research, Disorder, DSM-IV codes, Injury, Dementia, Clonazepam, Parkinsonism, Dream, Patient, Sleep disorder, Risk, Lewy body, Diagnosis, Erectile dysfunction, Obstructive sleep apnea, Color, Synucleinopathy, Disease, REM, Pharmaceutical industry

The disorder, known as REM sleep behavior disorder, or RBD in the medical field, affects around 1% of the general population worldwide and about 2% of adults over 65.

Key Points: 
  • The disorder, known as REM sleep behavior disorder, or RBD in the medical field, affects around 1% of the general population worldwide and about 2% of adults over 65.
  • The Conversation talked with Anelyssa D'Abreu, a neurologist who specializes in geriatric neurology, to explain what researchers know about the condition’s links to dementia.

1. What is REM sleep behavior disorder?

    • REM sleep only comprises 20% to 25% of total sleep, but its proportion increases throughout the night.
    • But someone with REM sleep behavior disorder will act out their dreams.
    • Appropriate testing, including a sleep study, are needed to determine if a patient has REM sleep behavior disorder, as opposed to another disorder, such as obstructive sleep apnea.
    • REM sleep behavior disorder can occur at any age, but symptoms usually start with people in their 40s and 50s.

2. What causes REM sleep behavior disorder?

    • In some cases of REM sleep behavior disorder, a clear cause cannot be identified.
    • In both situations, REM sleep behavior disorder may be associated with synucleinopathies, a group of neurodegenerative disorders in which aggregates of the protein α-synuclein accumulate in brain cells.
    • REM sleep behavior disorder may precede these diseases or occur at any time during the disease process.

3. What are the links between the sleep disorder and dementia?

    • REM sleep behavior disorder may be the first symptom of Parkinson’s disease or dementia with Lewy bodies.
    • After 12 years, 73.5% of those with REM sleep behavior disorder had developed a related neurodegenerative disorder.
    • REM sleep behavior disorder may also be observed in other neurodegenerative disorders such as Alzheimer’s disease and Huntington’s disease, but at much lower rates.

4. Does an early diagnosis help?

    • RBD, in that scenario, is an early sign of those disorders.
    • At this time, there are no approved therapies to prevent the onset of these neurodegenerative diseases in those with REM sleep behavior disorder.
    • We also recommend measures to avoid injury, such as removing breakable objects from the room, protecting windows and padding floors.

MICHAEL J. FOX FOUNDATION ANNOUNCES SIGNIFICANT BREAKTHROUGH IN SEARCH FOR PARKINSON'S BIOMARKER

Retrieved on: 
Wednesday, April 12, 2023
Insurance, PD, RBD, GBA, The Michael J. Fox Foundation, Pathology, Doctor of Philosophy, Dementia, Alzheimer's disease, Dream, Patient, MD, Three-body problem, MJFF, Synuclein, Risk, Anosmia, Disease, Science, DaT scan, University, Lancet Neurology, University of Texas at Austin, Mutation, Research, Parkinson's disease, Data, Medicine, Alpha-synuclein, Biology, Diagnosis, LRRK2, DLB, Biomarker, Sleep disorder, DAT, Edmond, Connie, The Lancet, Amprion, Drug development, Multiple system atrophy, Rapid eye movement sleep behavior disorder, Neurodegenerative disease, ASAP, Movement, MSA, Physician, REM, Medical imaging, Pharmaceutical industry, Dietary supplement, Nursing

Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.
  • "Using αSyn-SAA, we are already unlocking new understanding of Parkinson's, which will transform every aspect of drug development and ultimately clinical care.
  • Only about 30 percent of at-risk individuals with a positive seed amplification assay result also had significant dopamine loss.
  • In addition to ASAP, PPMI is supported by the Edmond J. Safra Foundation, the Farmer Family Foundation and Connie and Steve Ballmer.

MICHAEL J. FOX FOUNDATION ANNOUNCES SIGNIFICANT BREAKTHROUGH IN SEARCH FOR PARKINSON'S BIOMARKER

Retrieved on: 
Wednesday, April 12, 2023
Insurance, PD, RBD, GBA, The Michael J. Fox Foundation, Pathology, Doctor of Philosophy, Dementia, Alzheimer's disease, Dream, Patient, MD, Three-body problem, MJFF, Synuclein, Risk, Anosmia, Disease, Science, DaT scan, University, Lancet Neurology, University of Texas at Austin, Mutation, Research, Parkinson's disease, Data, Medicine, Alpha-synuclein, Biology, Diagnosis, LRRK2, DLB, Biomarker, Sleep disorder, DAT, Edmond, Connie, The Lancet, Amprion, Drug development, Multiple system atrophy, Rapid eye movement sleep behavior disorder, Neurodegenerative disease, ASAP, Movement, MSA, Physician, REM, Medical imaging, Pharmaceutical industry, Dietary supplement, Nursing

Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.
  • "Using αSyn-SAA, we are already unlocking new understanding of Parkinson's, which will transform every aspect of drug development and ultimately clinical care.
  • Only about 30 percent of at-risk individuals with a positive seed amplification assay result also had significant dopamine loss.
  • In addition to ASAP, PPMI is supported by the Edmond J. Safra Foundation, the Farmer Family Foundation and Connie and Steve Ballmer.

ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia

Retrieved on: 
Thursday, March 30, 2023
PD, Therapy, Disease, Movement disorder, Moca, Rett syndrome, Dopamine, CNS, Central nervous system, II, Rapid eye movement sleep behavior disorder, MDS, Montreal Cognitive Assessment, DSM-IV codes, Patient, RBDSQ, L-DOPA, ITT, III, OLE, Safety, Pharmaceutical industry

NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other Central Nervous System (CNS) disorders, reports preliminary 48-week open-label extension Parkinson’s disease dementia ANAVEX®2-73-PDD-EP-001 Phase 2 study data which demonstrated longitudinal beneficial effects of ANAVEX®2-73 on the prespecified primary and secondary objectives, as well as planned primary and key secondary endpoints which will be utilized in a forthcoming pivotal study of ANAVEX®2-73 in Parkinson’s disease.

Key Points: 
  • Parkinson’s disease (PD) is a chronic, debilitating CNS disease and the second largest age-related disorder after Alzheimer’s disease.2 This study demonstrates for the first-time that patients’ clinical symptoms consistently improve longitudinally during the 48-week ANAVEX2-73-PDD-EP-001 Phase 2 study under active ANAVEX®2-73 treatment in Parkinson’s disease.
  • The 48-week Open Label Extension (OLE) ANAVEX2-73-PDD-EP-001 Phase 2 study was offered to participants after completion of the double-blind placebo-controlled ANAVEX2-73-PDD-001 Phase 2 study.
  • However, a consistent improvement was observed during the extension phase when patients resumed ANAVEX®2-73 treatment.
  • These results are consistent with the pattern observed for all efficacy measures in the extension phase (see Chart and Table).6

GRIN Therapeutics Announces First Patient Dosed in Phase 1B Clinical Trial with Radiprodil for Treatment of GRIN-related Disorders

Retrieved on: 
Thursday, March 23, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Epilepsy, Seizure, Maintenance, Rapid eye movement sleep behavior disorder, GOF, DSM-IV codes, Sleep, GRIN, Pharmacokinetics, NMDA, Honeycomb, Research, GRIN1, Intellectual disability, Human genetics, NR2B, Genetics, Patient, Spectrum, MPH, Therapy, Gene, Safety, SLC6A1 epileptic encephalopathy, Pharmaceutical industry, GRIN2B, GRIN2A, GRIN2D

GRIN Therapeutics Inc., a leader in development of therapies to treat GRIN-related disorders, today announced that the first patient has been dosed in the Honeycomb Study, the Company’s Phase 1B clinical trial of radiprodil, an investigational NR2B-negative allosteric modulator in development for the treatment of GRIN-related disorders.

Key Points: 
  • GRIN Therapeutics Inc., a leader in development of therapies to treat GRIN-related disorders, today announced that the first patient has been dosed in the Honeycomb Study, the Company’s Phase 1B clinical trial of radiprodil, an investigational NR2B-negative allosteric modulator in development for the treatment of GRIN-related disorders.
  • Radiprodil targets the hyperactive receptors associated with the development and progression of GRIN-related disorders by potently and selectively modulating the Nmethyl-D-aspartate (NMDA) receptor subtype 2B (NR2B).
  • People living with GRIN-related disorders present with a spectrum of symptoms including epilepsy, behavioral disorders, autism, intellectual disability, and movement disorders.
  • Currently, there are no disease-specific treatment options for GRIN-related disorders.

Biometrics Leader LifeQ Revolutionizes Healthcare with Disease Screening and Early Detection

Retrieved on: 
Monday, March 20, 2023
Mont Blanc, Fossil, Blood pressure, Medicine, Night, Probability, Photoplethysmogram, Cardiomyopathy, TAG Heuer, Health, Bradycardia, Classification, HOCM, Atrial fibrillation, Respiratory rate, COVID-19, Sleep, Restless legs syndrome, Arteriosclerosis, Narcolepsy, Sleep apnea, Acute (medicine), Tachycardia, Hypersomnia, Hypertension, Aortic stenosis, Insomnia, PLMD, Patient, Rapid eye movement sleep behavior disorder, Physician, Cardiovascular disease, PPG, Korea Disease Control and Prevention Agency, Diagnosis, Heart rate, Skin temperature, Chronic condition, Sleepwalking, Bigeminy, Conditional sentence, Disease, REM, Pharmaceutical industry, Medical device, Suunto

ATLANTA, March 20, 2023 /PRNewswire/ -- LifeQ, the company that uses globally-recognized watch brands to gather personalized, clinical-grade data, announced it can detect as many as 40 sleep and cardiovascular disorders with smart watches and other wearable devices, with an anticipated 100 diseases and disorders within the next two years—revolutionizing healthcare and improving consumers' lives. LifeQ co-founders Laurence (Laurie) Olivier, CEO, and Dr. Franco du Preez, Chief Science Officer, made the announcement.

Key Points: 
  • LifeQ co-founders Laurence (Laurie) Olivier, CEO, and Dr. Franco du Preez, Chief Science Officer, made the announcement.
  • LifeQ-enabled devices will help busy clinicians to detect important medical conditions, enable data-driven disease classification as well as facilitate disease prevention.
  • Screening for and flagging disease using wearables is possible through LifeQ's unique combination of photoplethysmography (PPG) and computational systems biology approach.
  • Wearable devices will soon enable insights for hundreds of diseases, providing a personalized action plan and a truly preventative approach to healthcare.

CND Life Sciences Partners with Soleo Health to Broaden the Awareness and Availability of CND's Cutaneous Neurodiagnostic Tests

Retrieved on: 
Thursday, November 3, 2022
Blood pressure, Media, URAC, Digestion, Education, Neurology, Research, NIA, Perspiration, Partnership, Neuromuscular Disorders, Neurodegeneration, Solution, Autonomic neuropathy, Company, Practitioner, LLC, Synucleinopathy, Pharmacy, National, Dementia, Dysautonomia, NINDS, CND, Pure autonomic failure, Diagnosis, Sleep, Patient, Leadership, Lewy body, SBIR, ACHC, Heart rate, Distinction, Rapid eye movement sleep behavior disorder, Family, Physician, REM, Parkinson's disease, Multiple system atrophy, NIH, Movement disorders, Joint Commission, Health, Medicine, MD, Management, Pharmaceutical industry, Public relations, Stroke, PHOENIX, Ageing

PHOENIX and FRISCO, Texas , Nov. 3, 2022 /PRNewswire/ -- CND Life Sciences (http://cndlifesciences.com), an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, is pleased to announce its strategic collaboration with Soleo Health®, a leading national provider of complex specialty pharmacy services, to educate neuromuscular specialists and other neurologists on CND's novel Syn-One Test® and its intraepidermal nerve fiber density assay called Small-Fiber Dx™.

Key Points: 
  • "We are in an era of medicine where precision diagnostics have become increasingly crucial to optimize patient care," said Rick Morello, CND Life Sciences' Chief Executive Officer.
  • "We are quite pleased to work with Soleo Health as a key partner to help CND educate neurologists who could benefit most from incorporating Syn-One and other cutaneous neurodiagnostics into their practice."
  • We are grateful that Soleo Health will help CND educate clinicians on the Syn-One Test and how it can be used effectively in patient care."
  • Additionally, Soleo Health operates more than 40 infusion centers throughout the U.S.
    Visit www.soleohealth.com or connect with Soleo Health on LinkedIn , Facebook and Twitter for more information.

CND Life Sciences Awarded Third NIH SBIR Grant to Study the Syn-One Test® in Patients Diagnosed with REM Sleep Behavior Disorder (RBD)

Retrieved on: 
Thursday, October 6, 2022
Lewy body, National Institute, Movement, Risk, PD, REM, Diagnosis, Neurodegeneration, Patient, MSA, Behavioural sciences, Sleep, Government budget balance, National Institute of Neurological Disorders and Stroke, Parkinson's disease, Research, NIH, Lists of diseases, CND, National Institute on Aging, NIA, Dementia, Synucleinopathy, SBIR, Psychiatry, MD, Pure autonomic failure, NAPS, AI, RBD, National, Neurology, PAF, Multiple system atrophy, DLB, Alpha-synuclein, Gold, Stanford University, Dysautonomia, Radical behaviorism, Stroke, Rapid eye movement sleep behavior disorder, Movement disorders, Pathology, Pharmaceutical industry, Medical imaging

PHOENIX, Oct. 6, 2022 /PRNewswire/ -- CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH). This is the third NIH SBIR Phase II award for the company to study and advance the clinical application of the Syn-One Test, the only commercially available test that uses skin biopsies to help clinicians diagnose a synucleinopathy, a family of neurodegenerative diseases that includes Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), pure autonomic failure (PAF) and REM sleep behavior disorder (RBD).

Key Points: 
  • Patients diagnosed with RBD experience vivid, often disruptive dreams associated with simple or complex motor behavior during the REM phase of sleep.
  • The success of future treatments for these disorders will be tied to how precisely and early we can understand the patient's pathology," explained Levine.
  • Founded in 2017, CND Life Sciences is dedicated to supporting the care of patients facing the potential diagnosis of a neurodegenerative disease and other neurological conditions.
  • The company has research collaborations with multiple biopharmaceutical companies and has been awarded three prestigious NIH SBIR grants to advance the validation and clinical utility of its Syn-One Test.

Companion Animal Health Market Report 2022: Increasing Initiatives by Government and Animal Welfare Associations Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, September 16, 2022
Veterinary, Health, Probiotic, Global, Customer support, AUD, Alameda East Veterinary Hospital, CHF, Pet, Acquisition, Prebiotic (nutrition), Growth, GBP, USD, Decision-making, Strategic management, Hormone, JPY, Use, Dog, CAD, Cat, Vaccine, Value, Rapid eye movement sleep behavior disorder, Research, Horse, Business Growth Fund, Market share analysis, Amino acid, Enzyme, CAGR, Retail, Mineral, Medication, Ectoparasiticide, EUR, Vitamin, Antibiotic

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF.

Key Points: 
  • The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF.
  • This research report categorizes the Companion Animal Health to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Animal, the market was studied across Cats, Dogs, and Horses.
  • Based on Indication, the market was studied across Behavioral Disorders, Dental Diseases, Dermatologic Diseases, Infectious Diseases, and Orthopedic Diseases.
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.